Clinical Research
Copyright ©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 7, 2007; 13(5): 748-753
Published online Feb 7, 2007. doi: 10.3748/wjg.v13.i5.748
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Crohn’s disease activity index (CDAI) was decreased in patients with active Crohn’s disease (n = 10) after 4-wk treatment with mastic caps (aP < 0. 05). Horizontal bars represent the mean value (± SE).
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 C-reactive protein (CRP) concentrations in patients with active Crohn’s disease (n = 10) before and after 4-wk treatment with mastic caps (aP < 0. 05). Horizontal bars represent the mean value (± SE).
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Plasma concentrations of interleukin-6 (IL-6) were suppressed in patients with active Crohn’s disease (n = 10) after 4-wk treatment with mastic caps (aP < 0. 05). Horizontal bars represent the mean value (± SE).
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Plasma total antioxidant potential (TAP) was upregulated in patients with active Crohn’s disease (n = 10) after 4-wk treatment with mastic caps (aP < 0. 05), indicating absorption of antioxidants and an improved in vivo antioxidant status. Horizontal bars represent the mean value (± SE).